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The metabolism of 2Shydroxyvitamin DJ [25(OH)D,] was examined in several phagocytic cells including 
alveolar macrophages and myeloid leukemia cells (Ml, HL-60 and U937). Phagocytic cells converted 
25(OH)D, to IO-oxo-19-nor-2Shydroxyvitamin D3 and a new metabolite. The former metabolite was domi- 
nant in shorter incubation periods (1 h), whereas the latter dominated over longer incubation periods (24 h). 
The new metabolite was produced from 25(OH)D, directly but not through lo-oxo-19-nor-25-hydroxyvi- 
tamin D3. The new metabolite was unequivocally identified as 8a,25-dihydroxy-9,10-seco-4,6,10( 19)~chole- 
statrien-3-one. These results suggest hat phagocytic cells somehow promote oxidation of the triene part 
of vitamin D compounds. 
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8a,25-Dihydroxy-9,1 O-seco-4,6,10( 19)-cholestatrien-3-one 
1. INTRODUCTION 
Recently, much attention has been focused on 
the metabolism of vitamin D3 in phagocytic cells. 
Phagocytic cells such as human blood leukocytes 
[ 11, monocytes [2] and tissue macrophages [l-3], 
and their transformed cells (HL-60 and U937) 
[4-71 have been reported to metabolize 
2%hydroxyvitamin D3 [25(OH)D3] to more polar 
metabolites including lo-oxo-19-nor-25-hydroxy- 
vitamin D3 [10-0x0-1 9-nor-25(OH)D3]. This meta- 
bolite has two isomers, 5E and 5Z forms. The 
former structure is similar to that of la,25-dihy- 
droxyvitamin D3 [1&,25(OH)2D3], the active form 
of vitamin D3, because the 3/?-hydroxyl function of 
(5E)-lO-oxo-19-nor-25(OH)D3 occupies the posi- 
Correspondence address: T. Suda, Department of 
Biochemistry, School of Dentistry, Showa University, 
l-5-8 Hatanodai, Shinagawa-ku, Tokyo 142, Japan 
tion of the la-hydroxyl function of luu,25(OH)2D3. 
These results led us to consider that the SE form of 
lo-oxo-19-nor-25(OH)D3 might be responsible for 
inducing monocytic differentiation. It has also 
been pointed out that this metabolite migrates at a 
similar position to 1~,25(OH)zD3 in a straight- 
phase high-pressure liquid chromatography 
(HPLC) system using 10% 2-propanol in hexane, 
the traditional chromatographic system for 
separating la,25(OH)2D3. However, neither the 
role nor the regulation of its production has been 
established. 
In the course of investigating the metabolism of 
25(OH)D3 in phagocytic cells, we found a new 
metabolite of 25(OH)Ds which migrated at a 
similar position to 24R,25_dihydroxyvitamin D3 
[24R,25(OH)zD3] in four different HPLC systems. 
The metabolite has now been identified as 
8a,25-dihydroxy-9,10-seco-4,6,10(19)-cholestatri- 
en-3-one. Here, we examined the relationship be- 
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tween the production of the two metabolites, 
lo-oxo-19-nor-25(OH)Ds and the new metabolite, 
in phagocytic cells. 
2. MATERIALS AND METHODS 
2.1. Animals and drugs 
Male mice, 6-g-week-old ddy strain, were ob- 
tained from Shizuoka Laboratory Animal Center 
(Shizuoka). 25(OH)D3, la,25(OH)zD3 and 
24R,25(OH)zD3 were kindly donated by Dr I. Mat- 
sunaga (Chugai Pharmaceutical Co., Tokyo). 
(5E)- and (5Z)-lO-oxo-l9-nor-25(OH)D3 and 
25,26S_dihydroxyvitamin D3 [25,26S(OH)zD3] 
were synthesized in our laboratory. 25(OH)- 
[26,27-3H]D3 (spec. act. 20.6 Ci/mmol) was ob- 
tained from Amersham (England). 
2.2. Cells 
Alveolar macrophages were collected by the 
tracheobronchial lavage method and purified as 
reported in [8]. The murine myeloid leukemia cell 
line (Ml, clone T22) was kindly donated by Dr M. 
Hozumi (Saitama Cancer Center Research In- 
stitute, Saitama). The human promyelocytic 
leukemia cell line (HL-60) was provided by Dr H. 
Hemmi (Tohoku University, Sendai). The human 
monoblast-like lymphoma cell line (U937) was pro- 
vided by Dr K. Takeda (Showa University, 
Tokyo). 
2.3. Incubations of phagocytic cells with 
Phagocytic cells (7 x 106) were incubated with 
1 &i 25(OH)t3H]D3 in 3.5 ml of a serum-free 
medium for l-36 h at 37°C under 5% COZ-95% 
air. The serum-free medium-consisted of a mixture 
of RPM1 1640, Dulbecco’s modified Eagle’s MEM 
and Ham’s F-12 (Gibco, Grand Island, NY) 
(2: 1: 1) containing 2.219 mg/ml of sodium bicar- 
bonate, 100 pg/ml of streptomycin sulfate, 
100 U/ml of penicillin G potassium, 8.47 ng/ml of 
selenous acid, 110 pug/ml of sodium pyruvate and 
1 pg/ml of human transferrin (Sigma, St. Louis, 
MO). After incubation, the cells and medium were 
extracted together [9], and the samples were ap- 
plied to a preparative silica Sep-Pak cartridge col- 
umn (Waters, Milford, MA) [lo]. The fraction 
containing dihydroxy metabolites of vitamin D3 
was subjected to Waters HPLC, pump model 
6000 A, equipped with a Finepak Sil column 
(0.46 x 25 cm, Jasco, Tokyo). The column was 
eluted with 10% 2-propanol in hexane at a flow 
rate of 1 ml/min. Fractions were collected every 
30 s and the radioactivity of the eluate was 
measured with a liquid scintillation counter. 
3. RESULTS 
Alveolar macrophages incubated for 1 h with 
25(OH)[3H]D3 produced lo-oxo-19-nor-25(OH)D3 
as a mixture of 5E and 5Z isomers (fig.lA). The 
natural 5E isomer was accompanied by the 5Z 
isomer photochemically produced, because a 
special precaution was not taken to avoid exposure 
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Fig. 1. HPLC profiles of the metabolites of 
25(OH)[3H]D3 produced by alveolar macrophages 
incubated with 25(OH)[3H]D3 for 1 h (A) and 24 h (B). 
Lipid extracts of the incubation mixture iere first 
subjected to a silica Sep-Pak cartridge column. A 
radioactive fraction eluted with 60% ethyl acetate in n- 
hexane was applied to HPLC (Finepak Sil column, 
0.46 x 25 cm, 10% 2-propanol in hexane, 1 ml/min, 
monitored at 265 nm). Arrows show the elution 
positions of the authentic vitamin D3 compounds. 
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of the experimental vessels to room light during in- 
cubation and chromatographic separation. The 
production of the metabolite attained a maximum 
at 1 h and decreased thereafter (fig.2A). For- 
mation of IO-oxo-19-nor-25(OH)D3 was also 
observed when 25(OH)D3 was allowed to stand for 
l-72 h at 37°C under 5% CO2-95% air in the 
medium without the cells (fig.2B). Formation 
of the metabolite in the medium alone increased 
time-dependently and attained a plateau at 48 h. 
The structures of (5E)- and (5Z)-IO-oxo-19- 
nor-25(OH)D3 were confirmed by ultraviolet 
(maximum at 310 nm), mass spectra [402(M+), 
384, 369, 359, 273 and 1771, and chemical syn- 
thesis. 
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When alveolar macrophages were incubated 
with 25(OH)[3H]D3 for a longer time, another 
radioactive peak appeared at approx. 17 min 
(fig.lB). The production of the new metabolite in- 
creased time-dependently and reached a maximum 
at 12-24 h (fig.2A). This metabolite was not pro- 
duced when 25(OH)D3 was allowed to stand at 
37°C in the medium without the cells. 
The elution position of the new metabolite was 
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Fig.2. Time course of the change in the rate of 
conversion of 25(OH)Ds to lo-oxo-l9-nor-25(OH)Ds 
(-) and the new metabolite (- - -). Alveolar 
macrophages were incubated with 25(OH)[‘H]D3 for 
l-36 h (A). 25(OH)[3H]Ds was allowed to stand in 
medium without macrophages for l-72 h (B). Points 
and bars represent means + SE of 3-6 independent sets 
of experiments. indicated. 
Fig.3. Cochromatography of the new metabolite with 
authentic vitamin Ds compounds on three different 
HPLC systems. The radioactive peak eluting at 17 min 
on the HPLC system shown in fig.lB was pooled and 
cochromatographed with authentic vitamin Ds 
compounds on three different HPLC systems: (i) 
Lichrosorb Si 60 column (0.46 x 25 cm), 2% methanol 
in dichloromethane, 1 ml/min (A); (ii) same column as 
in (i), hexane/dichloromethane/methanol (16: 2 : l), 
1 ml/min (B); (iii) Finepak Sil Cr8 column (0.46 x 
25 cm), 15% water in methanol, 1 ml/min (C). The solid 
line shows the absorbance at 270 nm and the bar 
represents radioactivity in each I-min fraction. Arrows 
show the elution positions of the authentic compounds 
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compared with those of authentic vitamin D com- 
pounds in three different HPLC systems besides 
the one shown in fig. 1: a straight-phase column 
with methanol-dichloromethane (fig.3A) and that 
with hexane-dichloromethane-methanol solvent 
systems (fig.3B), and a reverse-phase column with 
water-methanol (fig.3C). The new metabolite was 
eluted in the vicinity of 24R,25(OH)~Ds in these 
three HPLC systems, but did not comigrate to the 
same position of 24R,25(OH)zD~. 
The time course of the production of the two 
metabolites (fig.ZA) led us to examine the 
possibility that the new metabolite is derived from 
IO-oxo-19-nor-25(OH)Ds. lo-Oxo-19-nor-25(OH)- 
[3H]D3 was synthesized by allowing 25(OH)[3H]D3 
to stand for 2 days at 37’C in the medium alone. 
When incubated with alveolar macrophages, 
10-oxo-19-nor-25(OH)[3H]D3 was not converted to 
the new metabolite at any incubation times (not 
shown). 
Metabolism of 25(OH)D3 was also studied in 
several lines of mouse and human myeloid 
leukemia cells (Ml, U937, and HL-60). All of these 
myeloid cells produced the two metabolites, 
lo-oxo-19-nor-25(OH)D3 and the new metabolite. 
The mode of production of the two metabolites by 
these cells was similar to that by alveolar 
I [Al 
Fig.4. Conversion of 25(OH)Ds to lo-oxo-19-nor- 
25(OH)D3 (A) and the new metabolite (B). Phagocytic 
cells (7 x 106) (alveolar macrophages, Ml, U937, and 
HL-60) were incubated with 1 &i 25(OH)[3H]D3 for 1 h 
(empty columns) or 24 h (hatched columns). Columns 
and bars represent means f SE of 3-4 independent sets 
of experiments. 
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The structure of the new metabolite, &r,25- 
dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one. 
macrophages; lo-oxo-19-nor-25(OH)D3 was the 
dominant metabolite at 1 h, while the new 
metabolite was the major metabolite at 24 h 
(fig.4). 
The new metabolite was isolated by incubating 
25(OH)D3 with Ml cells and unequivocally iden- 
tified as 8a,25-dihydroxy-9,10-seco-4,6,10( 9)- 
cholestatrien-3-one (fig.5) on the basis of its 
ultraviolet (maximum at 295 nm and minimum at 
245 nm), infrared (presence of a conjugated car- 
bony1 group at 1660 cm-‘), mass (M+: 414 m/e), 
and ‘H-NMR spectra. The stereochemistry of the 
hydroxyl group newly introduced into the 
8-position was determined to be cy by chemical syn- 
thesis. Details of the identification work have been 
submitted. 
4. DISCUSSION 
We found that the conversion of 25(OH)D3 to 
lo-oxo-19-nor-25(OH)D3 occurred in the presence 
and absence of phagocytic cells. The time course of 
the conversion of 25(OH)Ds to 10-0x0-19- 
nor-25(OH)D3 was, however, different between 
the presence and absence of alveolar macrophages. 
Formation of the metabolite attained a maximum 
at 1 h and decreased thereafter in the presence of 
macrophages, whereas it increased time-depen- 
dently in the absence of the cells. The rate of con- 
version of 25(OH)D3 to the metabolite was much 
higher in the absence of macrophages. Using 
solubilized kidney mitochondria, Brown and 
DeLuca [ll] have also reported that 10-0x0-19- 
nor-25(OH)D3 is produced when 25(OH)D3 is 
allowed to stand in a buffer alone and also in a 
reconstitution system without the P-450 fraction, 
but that its formation is suppressed by the addition 
of antioxidants. From these results they suggested 
that the production of lo-oxo-19-nor-25(OH)D3 
occurs via a mechanism involving peroxidation. 
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Our preliminary experiments have also indicated 
that the addition of divalent iron (Fe2’) with 
oxygen gas causes the conversion of 25(OH)D3 to 
(SE)-lo-oxo-19-nor-25(OH)D3 in the absence of 
phagocytic cells (unpublished). Phagocytic cells, 
however, somehow enhance this oxidation. These 
results confirm the suggestion of Brown and 
DeLuca [ll]. 
Longer incubations (12-36 h) of phagocytic 
cells with 25(OH)[3H]D3 produced another 
metabolite eluting at 17 min on HPLC. The new 
metabolite was unequivocally identified as 
&,25-dihydroxy-9,10-seco-4,6,10( 19)-cholesta-tri- 
en-3-one. In contrast to the production of 10-0x0- 
19-nor-25(OH)D3, the new metabolite was formed 
only in the presence of phagocytic cells. In addi- 
tion, the new metabolite was not produced when 
phagocytic cells were incubated with radioactive 
lo-oxo-19-nor-25(OH)D3, suggesting that the new 
metabolite is formed from 25(OH)D3 directly. 
It is interesting that the new metabolite migrated 
in the vicinity of authentic 24R,25(OH)~D3 in the 
four different HPLC systems (figs 1,3). During the 
preparation of the present manuscript, Reichel et 
al. [12] reported that HL-60 cells exposed to 
la,25(OH)2D3 produced 24,25(OH)zD3 from 
25(OH)D3. In our study, phagocytic cells were not 
exposed to 1a,25(OH)2D3 before incubation with 
25(OH)[3H]D3, and the production of 24,25- 
(OH)Z[~H]D~ was not observed. It is also in- 
teresting that Reichel et al. [12] did not find the 
new metabolite under their experimental condi- 
tions. Further studies are needed to define the rela- 
tionship between the formation of 24,25(OH)zD3 
and the new metabolite described here. 
A recent report has indicated that 25(OH)D3 is 
metabolized to la,25-(OH)zD3 in human alveolar 
macrophages treated in vitro with interferon-y 
[13]. In this study, we isolated the two metabolites 
oxidized at the triene part, lo-0x0-19-nor- 
25(OH)D3 and &,25-dihydroxy-9,10-seco-4,6, 
lO( 19)-cholestatrien-3-one. In the classical meta- 
bolism of vitamin D3, the non-triene part was 
oxidized at the la, 24-, 25- and 26-positions. It is 
important to clarify the mechanism underlying the 
differences of these two types of oxidation. The 
biological significance of the new metabolite must 
also be elucidated in the future. 
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